ClinicalTrials.gg
Not yet recruitingNCT07938528STENTLESS IIUpdated Nov 16, 2026

Strategy of Intracoronary Imaging Guided Drug-Coated Balloon Therapy for De Novo Lesions in Large Coronary Vessels

An interventional study of Intracoronary imaging and Angiography in De Novo Large Coronary Vessel, Drug-coated Balloon and Intravascular Ultrasound, sponsored by China National Center for Cardiovascular Diseases. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by China National Center for Cardiovascular Diseases · Not applicable, Interventional, and Treatment

How we know

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
2,570
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

A number of 2570 patients scheduled for percutaneous coronary intervention (PCI) with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm) suitable for DCB implantation are openly randomized 1:1 to either intracoronary imaging guidance or angiographic guidance groups. The primary objective is to determine whether the IVUS/OCT-guided DCB strategy reduces the incidence of target vessel failure (TVF) at 12 months compared with the coronary angiography (CAG)-guided strategy.

Read the detailed description

This study is a prospective, multicenter, open-label, randomized controlled trial designed to evaluate the efficacy and safety of IVUS/OCT-guided drug-coated balloon (DCB) strategy compared with a CAG-guided strategy in patients with de novo large coronary vessel lesions (reference vessel diameter ≧2.75 mm). Both groups will follow standardized angiographic safety criteria, with bailout drug-eluting stent (DES) implantation permitted when necessary. In the IVUS/OCT-guided group, lesion assessment, preparation, DCB treatment, and bailout stenting decisions will be optimized according to a predefined IVUS/OCT criterion, whereas the CAG-guided group will undergo treatment primarily based on angiographic assessment.

02

Conditions studied

  • De Novo Large Coronary Vessel
  • Drug-coated Balloon
  • Intravascular Ultrasound
03

In context

Lead sponsor

China National Center for Cardiovascular Diseases is the lead sponsor of 271 studies on the registry; 143 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must meet all of the following three criteria:

  1. Age ≥18 years;
  2. De novo lesions of large coronary vessels with the diameter of target lesion reference vessel ≥ 2.75 mm;
  3. One or more trial target vessel (LAD, LCX or RCA) is considered to require intervention and is suitable for treatment with DCB.

Exclusion criteria

Exclusion Criteria:

Participants who meet any of the following conditions are not eligible for inclusion:

  1. Patients with hemodynamically unstable acute coronary syndrome
  2. Previous percutaneous coronary intervention (including stent implantation, plain old balloon angioplasty, and DCB angioplasty) on the target vessel within 12 months
  3. In-stent restenosis requiring revascularization
  4. Complex Coronary Bifurcation Lesions*
  5. Lesions with any of the following anatomical characteristics are presumably not suitable for DCB treatment:

1) Chronic total occlusion* 2) Left main coronary artery lesion and left main bifurcation lesion 3) Venous or arterial graft lesion 4) Moderated-Severe tortuous, or severe angulated vessels 6. cardiogenic shock 7. Concurrent medical condition with a of less than 1 year. 8. Known to medications such as Aspirin, Heparin, antiplatelet drugs, or contrast

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
2,570 participants (estimated)

Study arms

  • Experimental
    Intracoronary imaging-Guided Drug-coated balloon strategy

    DCB diameter and length will be determined based on Intracoronary imaging measurements, with additional lesion preparation performed at the operator's discretion according to the predefined intravascular imaging optimization criteria.

    Procedure: Intracoronary imaging

  • Active comparator
    CAG-guided Drug-coated balloon strategy

    In the CAG-guided group, DCB treatment will be guided by conventional coronary angiography, with DCB diameter and length determined by visual angiographic assessment.

    Procedure: Angiography

Interventions

  • ProcedureIntracoronary imaging

    In the intracoronary imaging-guided group, lesion preparation will be guided by intravascular imaging findings, with additional balloon dilatation or specialized devices used as needed. Following lesion preparation and DCB treatment, repeat Intracoronary imaging will be performed to assess lumen gain, residual stenosis, dissection morphology, and elastic recoil. The acceptable minimum lumen area (MLA) is ≥ 4.2 mm², with a target optimization criterion of MLA ≥ 70% of the mean reference lumen area. Patients meeting both the intracoronary imaging criteria and angiographic safety criteria will proceed to DCB treatment. If these criteria are not achieved but angiographic safety criteria are satisfied and the patient remains clinically stable, further optimization may be considered. If angiographic safety criteria remain unmet after observation, bailout drug-eluting stent (DES) implantation will be performed.

  • ProcedureAngiography

    For patients randomized to the CAG-guided group, the selection of lesion preparation devices, DCB sizing, and the need for bailout stenting will be determined by the operators based on coronary angiographic findings and clinical judgment. Patients meeting the predefined angiographic safety criteria after lesion preparation will proceed to DCB treatment. Bailout drug-eluting stent (DES) implantation will be performed if angiographic safety criteria are not met.

06

What researchers measure

Primary outcomes

  1. Target vessel failure

    Incidence of a composite of cardiac death, target-vessel myocardial infarction and clinically indicated target vessel revascularization

    Time frame: 12 months

Secondary outcomes

  1. Device success

    * Successful delivery in time and inflation within 30-60 s of the allocated DCB device at the intended target lesion during an attempt with a DCB not previously used (first use) * Successful delivery at the target lesion with final in-device residual stenosis ≤ 30% (DCB) or ≤ 20% (DES) by core laboratory QCA (preferred methodology) or visual assessment * No rescue procedure by stent

    Time frame: 0 day (during index PCI)

  2. Procedure success

    Device success Freedom from in-hospital TVF

    Time frame: 7 days

  3. Periprocedural complications

    Incidence of a composite of cardiac death, periprocedural myocardial infarction, acute target lesion/vessel thrombosis, and acute target lesion/vessel occlusion

    Time frame: 48 hours

  4. Incidence of cardiac death

    Incidence of cardiac death

    Time frame: 1, 12, 24, 36, and 60 months

  5. Incidence of target-vessel myocardial infarction

    Incidence of target-vessel myocardial infarction

    Time frame: 1, 12, 24, 36, and 60 months

  6. Incidence of clinically indicated target vessel revascularization

    Incidence of clinically indicated target vessel revascularization

    Time frame: 1, 12, 24, 36, and 60 months

  7. Patient-oriented composite endpoint (PoCE)

    Incidence of a composite of all-cause mortality, any myocardial infarction, any stroke, and any revascularization

    Time frame: 1, 12, 24, 36, and 60 months

  8. all-cause mortality

    all-cause mortality

    Time frame: 1, 12, 24, 36, and 60 months

  9. Any myocardial infarction

    Any myocardial infarction

    Time frame: 1, 12, 24, 36, and 60 months

  10. Any stroke

    Any stroke

    Time frame: 1, 12, 24, 36, and 60 months

  11. Any revascularization

    Any revascularization

    Time frame: 1, 12, 24, 36, and 60 months

  12. Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding)

    Incidence of net clinical benefit (a composite of cardiac death, target-vessel myocardial infarction, clinically indicated target vessel revascularization and major bleeding (Bleeding type 3 or 5 according to the Bleeding ARC))

    Time frame: 1,12, 24, 36, and 60 months

  13. Incidence of BARC (Bleeding Academic Research Consortium [BARC] definition, type 2,3 or 5)

    Incidence of BARC (Bleeding Academic Research Consortium \[BARC\] definition, type 2,3 or 5)

    Time frame: 1, 12, 24, 36, and 60 months

  14. Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR

    Hierarchical composite clinical endpoint of cardiovascular death, TV-MI, and clinically driven TVR

    Time frame: 1, 12, 24, 36 and 60 months

  15. Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events

    Hierarchical composite clinical endpoint of any death, any stroke, any MI, BARC defined type 3 bleeding events, any revascularization and BARC type 2 bleeding events

    Time frame: 1, 12, 24, 36 and 60 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — Deidentified individual participant data that underlie the results reported in the primary publication will be made available to qualified researchers upon reasonable request and approval of a methodologically sound research proposal, subject to an appropriate data use agreement.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Beginning 36 months after publication of the primary study results and continuing for 5 years.

Access criteria: Deidentified individual participant data underlying the results reported in the primary publication will be available to qualified researchers who submit a methodologically sound research proposal. Requests will be reviewed by the study investigators and, where applicable, relevant institutional or ethics authorities. Proposals that substantially overlap with prespecified ongoing analyses may be deferred until completion of those analyses. Data will be provided for the purposes specified in the approved proposal, subject to an appropriate data use agreement and applicable privacy and data protection requirements.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Dec 2028, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2031
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938528
Responsible party
Erli Zhang (Principal Investigator, China National Center for Cardiovascular Diseases) — Principal investigator
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Nov 16, 2026

Study contacts

Erli Zhang
Contact
zhangerli@fuwaihospital.org
+86 18500853301

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion